Both Mounjaro and Wegovy have similar eligibility requirements
It is used along with a reduced-calorie diet and increased physical activity
In fact, a genetic Mendelian randomization study in 2024 found that having a genetic profile akin to being on GLP-1 RA therapy was associated with ~50% lower odds of ED, partly mediated by lower obesity, diabetes, and blood pressure
However, glutathione is easily broken down in the digestive system, and without protection the body absorbs very little
The incidence varies considerably between different medications and doses: Semaglutide (Ozempic): Vomiting occurs in approximately 5-10% of patients at diabetes doses Semaglutide (Wegovy): At the higher weight management dose (2.4mg), vomiting affects up to 16% of patients Liraglutide (Victoza): Vomiting affects approximately 5% of patients Liraglutide (Saxenda): At weight management doses, vomiting occurs in about 7-10% of patients Dulaglutide (Trulicity): Vomiting affects approximately 7-9% of patients Tirzepatide (Mounjaro): Vomiting occurs in approximately 5-10% of patients, varying by dose These side effects are most pronounced during the initial treatment phase, particularly in the first 48 weeks, and often diminish as the body adapts to the medication
